The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
- PMID: 14746530
- DOI: 10.1146/annurev.med.55.091902.104433
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
Abstract
The overexpression and aberrant function of members of the erbB family of receptors, particularly erbB1 (also known as epidermal growth factor receptor), and its ligands in many human cancers have provided a rationale for targeting this signaling network with novel approaches. erbB1 is a selective target for inhibiting cancers because its activation often confers a proliferative advantage. Activation of the erbB1 tyrosine kinase provides signals that drive dysregulated proliferation, invasion, metastasis, angiogenesis, and cell survival, and its inhibition has potential in both the treatment and prevention of these malignancies. Based on the structure and function of erbB1, two therapeutic strategies have been developed. The first uses human monoclonal antibodies (MAbs) generated against the receptor's ligand-binding extracellular domain. These MAbs block binding of receptor-activating ligands, and, in some cases, can induce receptor endocytosis and downregulation. The second uses small molecules that compete with adenosine triphosphate (ATP) for binding to the receptor's kinase pocket, thereby blocking receptor activation and the transduction of postreceptor signals. Early clinical studies suggest that both approaches are well tolerated and can induce clinical activity in many common malignancies.
Similar articles
-
The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11. doi: 10.1053/sonc.2003.50027. Semin Oncol. 2003. PMID: 12644979 Review.
-
The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S. J Clin Oncol. 2001. PMID: 11560969 Review.
-
ErbB-targeted therapeutic approaches in human cancer.Exp Cell Res. 2003 Mar 10;284(1):122-30. doi: 10.1016/s0014-4827(02)00104-0. Exp Cell Res. 2003. PMID: 12648471 Review.
-
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9. doi: 10.1053/sonc.2002.35642. Semin Oncol. 2002. PMID: 12422308 Review.
-
Rational bases for the development of EGFR inhibitors for cancer treatment.Int J Biochem Cell Biol. 2007;39(7-8):1416-31. doi: 10.1016/j.biocel.2007.05.008. Epub 2007 May 21. Int J Biochem Cell Biol. 2007. PMID: 17596994 Review.
Cited by
-
Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.Int J Mol Sci. 2021 Feb 12;22(4):1831. doi: 10.3390/ijms22041831. Int J Mol Sci. 2021. PMID: 33673213 Free PMC article. Review.
-
The EGFR phosphatase RPTPγ is a redox-regulated suppressor of promigratory signaling.EMBO J. 2023 May 15;42(10):e111806. doi: 10.15252/embj.2022111806. Epub 2023 Mar 29. EMBO J. 2023. PMID: 36988334 Free PMC article.
-
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.Int J Mol Sci. 2024 Jun 28;25(13):7131. doi: 10.3390/ijms25137131. Int J Mol Sci. 2024. PMID: 39000238 Free PMC article. Review.
-
HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.BMC Cell Biol. 2009 Oct 31;10:78. doi: 10.1186/1471-2121-10-78. BMC Cell Biol. 2009. PMID: 19878579 Free PMC article.
-
In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels.Pharm Res. 2010 Nov;27(11):2343-55. doi: 10.1007/s11095-010-0068-z. Epub 2010 Mar 2. Pharm Res. 2010. PMID: 20195708
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
